Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder

Trial Profile

Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Suvorexant (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use

Most Recent Events

  • 20 Jan 2026 Planned number of patients changed from 10 to 20.
  • 20 Jan 2026 Planned End Date changed from 1 Dec 2025 to 1 Jul 2026.
  • 20 Jan 2026 Planned primary completion date changed from 1 Dec 2025 to 1 Jul 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top